Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06610097 · ClinicalTrials.gov registry record · NA

TNBC Gut Microbiota During Neoadjuvant Treatment

A NA study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Scripps Health.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06610097 is a NA study of Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Scripps Health. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06610097, a NA study of Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Scripps Health.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The gut microbiome is made up of the microbes (such as bacteria, viruses, and other organisms too small to see with the naked eye) that live in the digestive tract and has been shown to be important in metabolizing food, extracting vitamins and nutrients from food, and maintaining a healthy gut lining. The gut microbiome plays an important role in overall health and has been shown to dynamically change in response to early-stage triple-negative breast cancer-directed therapies, which in turn has been associated with worse outcomes. As the gut microbiome can be further modulated with dietary changes during cancer treatment, it is an ideal potential modifiable risk factor in cancer patients. However, due to multiple confounding factors such as dietary intake, mood, and activity, its utility as part of the oncologic clinical assessment remains unclear. In this prospective randomized controlled study, the investigators propose to recruit up to 30 early-stage TNBC patients to randomize to a personalized nutritional intervention of a high-fiber diet coached by a registered dietician versus educational handout alone during neoadjuvant treatment. The investigators propose to study the gut microbiota through stool sample analysis among early-stage triple-negative breast cancer patients undergoing neoadjuvant (i.e. before surgery) chemotherapy +/- immunotherapy. The investigators will also study how the gut microbiota can be further modulated with a high-fiber diet, and the investigators hypothesize that a high-fiber diet may play a protective role in preserving gut microbial diversity. As part of the nutritional intervention, the investigators propose to administer nutritional counseling with a registered dietitian (RD) to increase fiber intake and tracking performance status, activity, and mood during neoadjuvant treatment. Finally, the investigators propose to survey participants after study completion through one-on-one interviews to determine whether participants experi

Interventions

  • OTHER Nutritional Counseling

Study Locations (1)

California

  • Scripps Clinic - La Jolla

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-07
Est. Completion 2026-06-30
Phase NA

Sponsor

Scripps Health

30 total trials

What the Registry Record Tells You About NCT06610097

The ClinicalTrials.gov registry entry for NCT06610097 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nutritional Counseling is the first listed.

NCT06610097 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06610097 about?

NCT06610097 is a clinical study titled "TNBC Gut Microbiota During Neoadjuvant Treatment". The gut microbiome is made up of the microbes (such as bacteria, viruses, and other organisms too small to see with the naked eye) that live in the digestive tract and has been shown to be important in metabolizing food, extracting vitamins and nutrients from food, and maintaining a healthy gut lini...

What is the current status of trial NCT06610097?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-07. Estimated completion is 2026-06-30.

What conditions does trial NCT06610097 study?

This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma.

What interventions are being tested in trial NCT06610097?

The interventions under investigation include: Nutritional Counseling (OTHER).

Who is sponsoring clinical trial NCT06610097?

This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06610097 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.